Eterna Therapeutics Inc (ERNA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Eterna Therapeutics Inc stock (ERNA) is currently trading at $0.21. Eterna Therapeutics Inc PS ratio (Price-to-Sales) is 1275.37. Analyst consensus price target for ERNA is $3.00. WallStSmart rates ERNA as Sell.
- ERNA PE ratio analysis and historical PE chart
- ERNA PS ratio (Price-to-Sales) history and trend
- ERNA intrinsic value — DCF, Graham Number, EPV models
- ERNA stock price prediction 2025 2026 2027 2028 2029 2030
- ERNA fair value vs current price
- ERNA insider transactions and insider buying
- Is ERNA undervalued or overvalued?
- Eterna Therapeutics Inc financial analysis — revenue, earnings, cash flow
- ERNA Piotroski F-Score and Altman Z-Score
- ERNA analyst price target and Smart Rating
Eterna Therapeutics Inc
📊 No data available
Try selecting a different time range
ERNA Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Eterna Therapeutics Inc (ERNA)
ERNA trades at a significant discount to its Graham intrinsic value of $382.98, offering a 100% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Eterna Therapeutics Inc (ERNA) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Eterna Therapeutics Inc (ERNA) Key Strengths (1)
Trading at 1.98x book value, attractively priced
Supporting Valuation Data
Eterna Therapeutics Inc (ERNA) Areas to Watch (5)
Company is destroying shareholder value
Revenue declining -94.10%, a shrinking business
Very expensive at 1275.4x annual revenue
Very low institutional interest at 1.79%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Eterna Therapeutics Inc (ERNA) Detailed Analysis Report
Overall Assessment
This company scores 16/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 8.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (1.98) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (1275.37) suggest expensive pricing. Growth concerns include Revenue Growth at -94.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -687.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -687.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -94.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ERNA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ERNA's Price-to-Sales ratio of 1275.37x trades 347% above its historical average of 285.01x (95th percentile), historically expensive. The current valuation is 85% below its historical high of 8778.28x set in Mar 2026, and 1159327% above its historical low of 0.11x in Dec 2008. Over the past 12 months, the PS ratio has compressed from ~8071.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Eterna Therapeutics Inc (ERNA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Eterna Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 1,000 with 94% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.15 indicates a conservative balance sheet with 3M in cash.
Spending 67600% of revenue (676,000) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 94% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -1M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 6.87, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Eterna Therapeutics Inc.
Bottom Line
Eterna Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Eterna Therapeutics Inc(ERNA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.